XML 55 R58.htm IDEA: XBRL DOCUMENT v3.20.1
Related Parties Transactions (Details Textual) - USD ($)
1 Months Ended 9 Months Ended 12 Months Ended
Oct. 15, 2019
Jul. 12, 2019
Jul. 02, 2019
May 12, 2019
Feb. 02, 2019
May 11, 2018
Sep. 25, 2017
Apr. 12, 2017
Aug. 31, 2019
Jun. 30, 2019
May 27, 2019
Feb. 27, 2019
Jan. 20, 2019
Dec. 31, 2018
Nov. 30, 2018
Aug. 25, 2018
Jun. 27, 2018
Jan. 31, 2018
Jan. 18, 2018
Dec. 31, 2017
Sep. 30, 2017
Jan. 26, 2017
Sep. 30, 2019
Sep. 30, 2018
Jul. 12, 2020
Dec. 31, 2019
Dec. 31, 2018
Related Parties Transactions (Textual)                                                      
Interest expenses                                                   $ 482,014 $ 462,751
Conversion price                 $ 7.00                                    
Convertion of debt                 $ 4,872,340                                    
Conversion of debt, shares                 696,051                                    
Related party transactions, description                                                     Since 2018, Mr. Tsung-Shann Jiang, Mr. Chang-Jen Jiang, Ms. Shu-Ling Jiang, and Ms. Mei-Ling Jiang have entered into various loans with the Company for working capital purpose in an aggregate amount of $795,340. These loans bear interest at 12% per annum and are due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $837,726 to 119,675 shares of the Company's common stock at a conversion price of $7.00 per share.
Outstanding advance balance                           $ 7,745,096                       425,689 $ 7,745,096
Keypoint Note [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate principal amount                                 $ 250,000                    
Interest rate percentage                                 8.00%                    
Related party transactions, description                                 On June 27, 2018, the Company issued an eighteen-month term unsecured convertible promissory note (the “Keypoint Note”) in an aggregate principal amount of $250,000 to Keypoint Technology Ltd. (“Keypoint”) (See Note 8).                    
Odaira Note [Member]                                                      
Related Parties Transactions (Textual)                                                      
Related party transactions, description                               On August 25, 2018, the Company issued an eighteen-month term unsecured convertible promissory note (the “Odaira Note”) in an aggregate principal amount of $250,000 to Yoshinobu Odaira (“Odaira”) (See Note 8).                      
Rgene Corporation [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate principal amount                           13,719                       $ 29,194 13,719
Loan agreement, description                                                   The loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan will be matured on December 31, 2019  
Accrued interest                           5,758                 $ 7,138       5,758
Asiangene Corporation [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate working capital                                                     $ 24,017
Accrued interest                                             235        
Amount of equivalent                     $ 3,343                                
Interest rate percentage                                                     0.00%
Outstanding advance balance                           160,000                 24,017     $ 24,017 $ 160,000
Asiangene Corporation [Member] | NT [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate working capital                     $ 100,000                                
Loan agreement, description                     The loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan will be matured on December 31, 2019.                                
BioFirst [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate working capital                                                 $ 21,317    
Aggregate principal amount   $ 150,000                                                  
Loan agreement, description                                                   Bears interest at 1% per month (or equivalent to 12% per annum  
Accrued interest                                                   $ 8,468  
Outstanding loan balance                                                   128,683  
Stock purchase agreement, description             On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision, and the Company has recorded the full amount of $3,000,000 due to BioFirst.                                        
Outstanding advance balance                           6,428,643                 142,688     24,182 6,428,643
BioFirst (Australia) [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate principal amount   $ 150,000       $ 40,000                                          
Accrued interest                                             3,968        
Interest rate percentage   12.00%       0.00%                                          
Loan maturity date   Dec. 31, 2019                                                  
Outstanding loan balance                                                   40,000 40,000
Other receivable from related parties                           0                       115,946 0
Advances bear interest, description   The advances bear interest 1% per month                                                  
LBG USA, Inc.[Member]                                                      
Related Parties Transactions (Textual)                                                      
Loan agreement, description                       The advances bear 0% interest rate and are due on demand.                              
Outstanding advance                           0                       $ 675 0
BioLite Taiwan [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate working capital                             $ 430,817                 $ 94,990      
Loan agreement, description                                                   The development costs shall be shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan.  
Interest rate percentage                             0.00%                 12.00%      
Loan maturity date                                               Apr. 14, 2020      
Other receivable from related parties                           0                         0
Conversion price                             $ 7.00                 $ 7.00      
Convertion of debt                             $ 428,099                 $ 97,864      
Conversion of debt, shares                             61,157                 13,981      
BioLite Taiwan [Member] | NT [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate working capital                             $ 13,295,000                 $ 2,950,000      
BioFirst [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate working capital                                       $ 625,646   $ 950,000          
Accrued interest                                             142,688     $ 24,182  
Interest rate percentage         12.00%                             12.00%           12.00%  
Loan maturity date         Feb. 01, 2020                             May 27, 2020              
Interest expenses                                             $ 22,359        
Conversion price         $ 7.00                             $ 7.00              
Convertion of debt         $ 693,000                             $ 625,646              
Conversion of debt, shares         99,000                             89,378              
Stock purchase agreement, description                   Pursuant to which the Company agreed to issue 428,571 shares of the Company’s common stock to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst.                                  
Advances bear interest, description                                             The advances bear interest 1% per month (or equivalent to 12% per annum).        
BioFirst [Member] | Conversion Agreements One [Member]                                                      
Related Parties Transactions (Textual)                                                      
Interest rate percentage                                       0.00%              
Conversion price                                       $ 7.00              
Convertion of debt                                       $ 597,128              
Conversion of debt, shares                                       85,304              
BioFirst [Member] | NT [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate working capital                                       $ 19,430,000              
BioLite BVI [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate working capital               $ 987,134                                      
Interest rate percentage               12.00%                                      
Loan maturity date       May 11, 2020       May 11, 2019                                      
Conversion price       $ 7.00                                              
Convertion of debt       $ 987,134                                              
Conversion of debt, shares       141,020                                              
BioLite BVI [Member] | NT [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate working capital               $ 30,000,000                                      
Everfront Biotech Inc. [Member]                                                      
Related Parties Transactions (Textual)                                                      
Investment and equity transfer agreement, description                                         Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by AsiaGene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. AsiaGene also agreed to loan the proceeds to the Company for working capital purpose. The non-secured loan bears 0% interest rate and is due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $160,000 to 22,858 shares of the Company’s common stock at a conversion price of $7.00 per share.            
YuanGene [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate working capital                                   $ 42,690 $ 50,000             $ 9,205  
Interest rate percentage                                   0.00% 12.00%             0.00%  
Loan maturity date                         Jan. 19, 2020           Jan. 19, 2019                
Conversion price                         $ 7.00         $ 7.00                  
Convertion of debt                         $ 50,000         $ 42,690                  
Conversion of debt, shares                         7,143         6,099                  
Related party transactions, description                                   Company entered into a Conversion Agreements to convert the remaining balance of $42,690 to 6,099 shares of the Company's common stock at a conversion price of $7.00 per share.                  
Outstanding advance balance                                                   $ 0  
Jiangs [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate working capital                                                   $ 40,031  
Aggregate principal amount                           $ 0                 $ 4,735       $ 0
Interest rate percentage                           0.00%                       0.00%  
Related party transactions, description                                                     Since 2018, the Jiangs have also advanced funds to the Company for working capital purpose in an aggregate amount of $353,050. The advances bear 0% interest rate and are due on demand. On August 4, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $353,050 to 50,436 shares of the Company's common stock at a conversion price of $7.00 per share.
Kimho [Member]                                                      
Related Parties Transactions (Textual)                                                      
Related party transactions, description     On July 2, 2019, the Company entered into an agreement with Kimho, starting from September 2019 with a fixed monthly retainer of $7,500 before the IPO and the amount will be increased to $13,000 after IPO. As of September 30, 2019 and December 31, 2018, the outstanding services charge was $7,500 and $0, respectively.                                                
Outstanding advance balance                                                 $ 21,500
Lion Gene [Member]                                                      
Related Parties Transactions (Textual)                                                      
Accrued interest                                                   255  
Lion Gene [Member] | NT [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate working capital $ 300,000                                                    
Amount of equivalent $ 10,020                                                    
Euro Asia [Member]                                                      
Related Parties Transactions (Textual)                                                      
Outstanding advance                           0                       12,000 0
Outstanding advance balance                                                 284,479
Due to shareholders [Member]                                                      
Related Parties Transactions (Textual)                                                      
Outstanding advance balance                                                 $ 12,000
Advances bear interest, description                                                   Company entered into several agreements with our shareholders. The advances bear interest from 12% to 13.6224% per annum.